Acquisition by Daniel Scavilla of 60000 shares of Globus Medical subject to Rule 16b-3

Read at macroaxis.com

Published over three months ago View all stories for GLOBUS MEDICAL | GLOBUS MEDICAL Hype Analysis

Globus insider trading alert for acquisition of stock option (right to buy class a common stock) by Daniel Scavilla, Officer: President, Ceo, on 8th of July 2024. This event was filed by Globus Medical with SEC on 2022-04-21. Statement of changes in beneficial ownership - SEC Form 4. Daniel Scavilla currently serves as executive vice president, chief commercial officer and president - trauma of Globus Medical

We analyze GLOBUS MEDICAL's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of GLOBUS MEDICAL using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of GLOBUS MEDICAL based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

When running GLOBUS MEDICAL's price analysis, check to measure GLOBUS MEDICAL's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GLOBUS MEDICAL is operating at the current time. Most of GLOBUS MEDICAL's value examination focuses on studying past and present price action to predict the probability of GLOBUS MEDICAL's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GLOBUS MEDICAL's price. Additionally, you may evaluate how the addition of GLOBUS MEDICAL to your portfolios can decrease your overall portfolio volatility.